Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
N/A
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 819 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
LB Pharmaceuticals Inc Common Stock
Market Cap
$974.72M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$971.18M
Net Profit Margin
1.96%
TTM Avg
-6.61%
3Y Avg
-1.16%
5Y Avg
6.17%
Market Cap
$977.74M
Net Profit Margin
19.87%
TTM Avg
-292.21%
3Y Avg
-499.51%
5Y Avg
-430.28%
Market Cap
$963.47M
Net Profit Margin
-727.04%
TTM Avg
-1969.28%
3Y Avg
-984.64%
5Y Avg
-984.64%
Market Cap
$980.71M
Net Profit Margin
-32.54%
TTM Avg
-35.87%
3Y Avg
-66.42%
5Y Avg
-187.72%
Market Cap
$947.79M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-3217.58%
Market Cap
$996.44M
Net Profit Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$942.80M
Net Profit Margin
-384.30%
TTM Avg
-367.92%
3Y Avg
-183.96%
5Y Avg
-122.64%
Market Cap
$940.80M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $974.72M | 0.00% | 0.00% | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $971.18M | 1.96% | -6.61% | -1.16% | 6.17% |
| MeiraGTx Holdings plc (MGTX)vs › | $977.74M | 19.87% | -292.21% | -499.51% | -430.28% |
| Aktis Oncology, Inc. (AKTS)vs › | $963.47M | -727.04% | -1969.28% | -984.64% | -984.64% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $980.71M | -32.54% | -35.87% | -66.42% | -187.72% |
| Savara Inc. (SVRA)vs › | $947.79M | 0.00% | 0.00% | 0.00% | -3217.58% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $996.44M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $942.80M | -384.30% | -367.92% | -183.96% | -122.64% |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $940.80M | 0.00% | 0.00% | 0.00% | 0.00% |
| MoonLake Immunotherapeutics (MLTX)vs › | $927.79M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
